Determination of Urinary Caffeine Metabolites As Biomarkers for Drug Metabolic Enzyme Activities

Overview

Journal Nutrients

Date 2019 Aug 22

PMID 31430927

Citations 6

Authors

Hyeong Jun Kim

Min Sun Choi

Shaheed Ur Rehman

Young Seok Ji

Jun Sang Yu

Katsunori Nakamura

Hye Hyun Yoo

Affiliations

Soon will be listed here.

Abstract

Caffeine is commonly taken via the daily dietary consumption of caffeine-containing foods. The absorbed caffeine is metabolized to yield various metabolites by drug-metabolizing enzymes, and measuring the levels of each caffeine metabolite can provide useful information for evaluating the phenotypes of those enzymes. In this study, the urinary concentrations of caffeine and its 13 metabolites were determined, and the phenotypes of drug metabolic enzymes were investigated based on the caffeine metabolite ratios. Human urine samples were pretreated using solid phase extraction, and caffeine and its metabolites were analyzed using liquid chromatography-tandem mass spectrometry. Based on the urinary caffeine metabolite concentrations, the caffeine metabolite ratios were calculated for six human subjects at specified time points after caffeine intake. Variations in urinary metabolite levels among individuals and time points were reported. In addition, the resultant enzyme activities showed different patterns, depending on the metabolite ratio equations applied. However, some data presented a constant metabolite ratio range, irrespective of time points, even at pre-dose. This suggests the possibility of urinary caffeine metabolite analysis for routine clinical examination. These findings show that urinary caffeine and the metabolite analysis would be useful in evaluating metabolic phenotypes for personalized medicine.

Citing Articles

Characterization the microbial diversity and metabolites of four varieties of Dry-Cured ham in western Yunnan of China.

Qin Y, Li W, Zhang W, Zhang B, Yao D, Zeng C Food Chem X. 2024; 22:101257.

PMID: 38495458 PMC: 10943036. DOI: 10.1016/j.fochx.2024.101257.

Caffeine and Its Antioxidant Properties-It Is All about Dose and Source.

osz B, Jitca G, Stefanescu R, Puscas A, Tero-Vescan A, Vari C Int J Mol Sci. 2022; 23(21).

PMID: 36361861 PMC: 9654796. DOI: 10.3390/ijms232113074.

Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for Human Cytochrome P450 Enzyme Induction.

Jacobs M, Kubickova B, Boshoff E Front Toxicol. 2022; 4:880818.

PMID: 35795225 PMC: 9252529. DOI: 10.3389/ftox.2022.880818.

Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.

Magliocco G, Desmeules J, Samer C, Thomas A, Daali Y Clin Transl Sci. 2022; 15(6):1482-1491.

PMID: 35338582 PMC: 9199893. DOI: 10.1111/cts.13263.

Caffeine metabolites are associated with different forms of caffeine supplementation and with perceived exertion during endurance exercise.

Whalley P, Paton C, Dearing C Biol Sport. 2021; 38(2):261-267.

PMID: 34079171 PMC: 8139353. DOI: 10.5114/biolsport.2020.98455.

References

Nordmark A, Lundgren S, Cnattingius S, Rane A . Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol. 1999; 47(4):397-402. PMC: 2014237. DOI: 10.1046/j.1365-2125.1999.00918.x. View

Chung W, Kang J, Park C, Cho M, CHA Y . Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther. 2000; 67(3):258-66. DOI: 10.1067/mcp.2000.104617. View

Pritsos C . Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2001; 129(1-2):195-208. DOI: 10.1016/s0009-2797(00)00203-9. View

Nyeki A, Buclin T, Biollaz J, Decosterd L . NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol. 2003; 55(1):62-7. PMC: 1884184. DOI: 10.1046/j.1365-2125.2003.01730.x. View

Schneider H, Ma L, Glatt H . Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 789(2):227-37. DOI: 10.1016/s1570-0232(03)00065-5. View

Aklillu E, Carrillo J, Makonnen E, Hellman K, Pitarque M, Bertilsson L . Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003; 64(3):659-69. DOI: 10.1124/mol.64.3.659. View

Aklillu E, Carrillo J, Makonnen E, Bertilsson L, Ingelman-Sundberg M . Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol. 2003; 59(7):533-6. DOI: 10.1007/s00228-003-0653-8. View

Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J . Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol. 2004; 60(1):17-21. DOI: 10.1007/s00228-003-0718-8. View

Caubet M, Comte B, Brazier J . Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J Pharm Biomed Anal. 2004; 34(2):379-89. DOI: 10.1016/S0731-7085(03)00528-4. View

10.

Ardan T, Kovaceva J, cejkova J . Comparative histochemical and immunohistochemical study on xanthine oxidoreductase/xanthine oxidase in mammalian corneal epithelium. Acta Histochem. 2004; 106(1):69-75. DOI: 10.1016/j.acthis.2003.08.001. View

11.

Thevis M, Opfermann G, Krug O, Schanzer W . Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis. Rapid Commun Mass Spectrom. 2004; 18(14):1553-60. DOI: 10.1002/rcm.1518. View

12.

Weimann A, Sabroe M, Poulsen H . Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 2005; 40(3):307-16. DOI: 10.1002/jms.785. View

13.

Marchei E, Pellegrini M, Pacifici R, Palmi I, Pichini S . Development and validation of a high-performance liquid chromatography-mass spectrometry assay for methylxanthines and taurine in dietary supplements. J Pharm Biomed Anal. 2005; 37(3):499-507. DOI: 10.1016/j.jpba.2004.11.013. View

14.

Pacher P, Nivorozhkin A, Szabo C . Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58(1):87-114. PMC: 2233605. DOI: 10.1124/pr.58.1.6. View

15.

Kitamura S, Sugihara K, Ohta S . Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet. 2006; 21(2):83-98. DOI: 10.2133/dmpk.21.83. View

16.

Rihs H, John A, Scherenberg M, Seidel A, Bruning T . Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta. 2006; 376(1-2):240-3. DOI: 10.1016/j.cca.2006.08.010. View

17.

Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini E . In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr. 2007; 21(2):190-200. DOI: 10.1002/bmc.736. View

18.

Ashihara H, Sano H, Crozier A . Caffeine and related purine alkaloids: biosynthesis, catabolism, function and genetic engineering. Phytochemistry. 2007; 69(4):841-56. DOI: 10.1016/j.phytochem.2007.10.029. View

19.

Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U . Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?. Eur J Clin Pharmacol. 2008; 65(4):411-7. DOI: 10.1007/s00228-008-0597-0. View

20.

Kot M, Daniel W . Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep. 2009; 60(6):789-97. View